Session 2: Cardiorenal, Metabolic, and Liver Disease Innovative Drug Development & Clinical Progress

Moderator: Jiahong ZHAO, CMO, CGeneTech

--09:00 | Innovative Drug R&D Concepts in Glucose Metabolism Diseases

Jiahong ZHAO, CMO, CGeneTech

--09:25 | Application of Dual-Targeting Peptides in Renal-Metabolic and Cardiovascular Fields

Speaker: Zhian HUANG, Marketing Head, Micot Pharmaceutical

--09:50 | Progress in Regenerative Islet Transplantation for Diabetes Research

Speaker: Xiaoyan WANG, CEO, Endocell

--10:15 | Coffee Break & Networking

--10:35 | Metabolic Reset via Transient Amino Acid Starvation: A Novel Platform for Obesity and Metabolic Disease

Speaker: Xiuyuan SHEN, Co-founder, ABRAM Therapeutics

--11:00 | Differentiating the Next Generation of GLP-1 Therapies

Speaker: Davide Garrisi, VP, Cardiovascular, Renal & Metabolism Therapeutic Area, Thermo Fisher PPD

--11:25 | R&D and Clinical Translation of a Globally First-in-Class FGF21R/GCGR/GLP-1R Tri-Agonist for Metabolic Diseases

Speaker: Yongliang FANG, COO, Doer Biologics

--11:50 | Panel Discussion

l Post-GLP-1 Era: Future Directions for Next-Generation Drugs

l Balancing Efficacy vs. Convenience: Oral vs. Injectable Formulations

--12:30 | Buffet Lunch & Networking

--14:00 | Latest Progress of THR-β Agonist HP515 in MASH Treatment

Speaker: Wu DU, SVP, Hinova Pharmaceuticals

--14:30 | Constructing a Full Life-Cycle Evaluation System for Metabolic Diseases: Animal Models and Clinical Translation Strategies from Obesity and Diabetes to MASH & CKLM

Speaker: Yujing ZHANG, Pharmacology Head, Guochen Biotechnology

--15:00 | Redefining Cardiometabolic Disease Management: Clinical Paradigm Shift Toward Comprehensive Treatment Strategies

Speaker: Baohong ZHANG, VP of Metabolic Business Unit, Harbour BioMed

--15:30 | Coffee Break & Business Networking

--15:50 | GLP-1 2.0 Era: Innovative Therapies Hardcore-Cracking the Industry Challenge of Weight Reduction

Speaker: Lin ZHANG, Medical Head, Benemae Pharmaceutical

--16:20 | Differentiated Differentiation Layout Strategies for GLP-1 Products

Speaker: Lei MEI, BD Director, Shanghai Minwei Biotechnology

--16:50 | Long-Acting Gene Therapy Development for Heart Failure and MASH

Speaker: Lei ZHAOi, VP, Taxell Therapeutics

--17:20 | Opportunities and Challenges in Small Nucleic Acid (RNAi/ASO) Drug Development for Metabolic Diseases

You Dong, Chief Medical Officer, Epigenic Therapeutics

18:00 | Closing

Session 1: ADC & Novel Antibody Therapeutics and Process Development

Theme: Next-Generation ADC Drug Development

Moderator:  Yanfeng ZHANG, President, Beilian Biotechnology

--09:00 | Global Debut of Nano-BsADC: R&D Journey and Future Development Insights for Novel Nano-BsADCs

Speaker: Qun Qu, Assistant to the Chairman, Keyuan Pharma

--09:25 | A Novel Therapy Targeting PTK7/FAP Bispecific Antibody-Drug Conjugate (BsADC)

Speaker: Jingen Xu, Head of New Technology Platform, Huabo Biopharm

--09:50 | Promega Tools for Developing Therapeutic ADCs

Speaker: Wanting Hou, Senior Senior Technical Applications Scientist, Promega

--10:15 | Coffee Break & Networking

--10:35 | Translational Medicine Research of Antibody-Drug Conjugates

Speaker: Peng Guo, Researcher, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences

--11:00 | Several Key Issues in the R&D and Innovation of ADC Drugs

Speaker: Zhenqing Feng, Professor, Nanjing Medical University

--11:25 | Highly Integrated Development Engine for Antibody Drugs

Speaker: Zhiyun Zhang, Chief Business Officer (CBO), Symray Biopharma

--11:50 | Panel Discussion: Trends of Next-Generation ADCs and Strategic Considerations for Corporate Global Expansion

--12:30 | Buffet Lunch & Networking

Theme: Development and Process of Novel Antibody Drugs

--14:00 | Early Optimization and Druggability Assessment of Bispecific/Multispecific Antibodies

Speaker: Song LI, VP of R&D, ImmuneOnco Biopharmaceuticals

--14:30 | R&D of Therapeutic Antibodies for Heart Failure Post-PCI in Acute Myocardial Infarction

Speaker: Yuangfang Ma, CEO, Yongxin Bio

--15:00 | Differentiated Inflammation Projects Related to TSLP & IL33 and VHH-Fc Nanobody Platform Technology

Speaker: Shuihua ZHANG, VP, Shenzhen NewDEL Biotech

--15:30 | Coffee Break & Business Networking

--15:50 | R&D of Novel Nanobodies Based on Synthetic Bioinformatic Technologies

Speaker: Ma Xingyuan, Professor, East China University of Science and Technology (ECUST)

--16:20 | Development and Clinical Progress of Next-Generation Antibody Drugs Targeting CTLA-4

Speaker: Mingyang GU, Assistant to Chairman, OncoC4

--16:50 | Application of Next-Generation Trispecific TCE in Oncology and Autoimmune Therapy

Speaker: Yingfeng HUANG, CEO, CytoCares

--17:20 | Panel Discussion

Clinical Value-Oriented—How to Turn an "Innovative Molecule" into a "Good Medicine"

--18:00 | Closing